Cargando…

1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina

BACKGROUND: Despite the current vaccination program in Argentina for older adults (OA), influenza continues to have severe consequences. Estimates based on Argentinian information surveillance system suggest that influenza-like illness reaches an average rate of 3,570/100,000 annually, a hospitaliza...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Van, Vizzotti, Carla, Uruena, Analia, Giglio, Norberto, Magneres, Maria Cecilia, Richmond, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253628/ http://dx.doi.org/10.1093/ofid/ofy210.1266

Ejemplares similares

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
por: Urueña, Analía, et al.
Publicado: (2022)

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
por: Postma, Maarten, et al.
Publicado: (2023)

1166. The Cost-Effectiveness Evidence of Enhanced Influenza Vaccines in Adults ≥65 Years of Age: A Literature Review and Decision-Making Implications
por: Giglio, David FismanNorberto, et al.
Publicado: (2023)

Single-Dose Universal Hepatitis A Immunization in 1-Year-Old Infants in Argentina: High Prevalence of Protective Antibodies up to 11 Years Following Vaccination
por: Urueña, Analia, et al.
Publicado: (2017)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
por: Boikos, Constantina, et al.
Publicado: (2022)

Public health and economic benefits of new pediatric influenza vaccination programs in Argentina
por: Giglio, Norberto, et al.
Publicado: (2012)

Meningococcal burden of disease in Argentina: 10 years epidemiologic review
por: Neyro, Silvina, et al.
Publicado: (2023)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
por: Cox, Freek, et al.
Publicado: (2015)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

1382. Varicella Burden Disease in Argentina: 4 Years after National Vaccination Strategy
por: Neyro, Silvina, et al.
Publicado: (2020)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Epidemiological study of influenza virus infections in young adult outpatients from Buenos Aires, Argentina
por: Santamaría, Cecilia, et al.
Publicado: (2008)

Influenza B vaccine lineage selection—An optimized trivalent vaccine
por: Mosterín Höpping, Ana, et al.
Publicado: (2016)

Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
por: Silveira, Fernando, et al.
Publicado: (2023)

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
por: You, Joyce HS, et al.
Publicado: (2014)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis
por: Coleman, Brenda L., et al.
Publicado: (2021)

14. A Comprehensive Real-World Analysis to Compare Adjuvanted Trivalent Influenza Vaccine and Trivalent High Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2018–19 Season among U.S. Elderly
por: Postma, Maarten, et al.
Publicado: (2020)

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
por: Kim, Yun-Kyung, et al.
Publicado: (2018)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age
por: Otten, Gillis, et al.
Publicado: (2018)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study
por: de Lusignan, Simon, et al.
Publicado: (2022)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2022)

Acquired immune responses to the seasonal trivalent influenza vaccination in COPD
por: Staples, K. J., et al.
Publicado: (2019)

Gulllain-Barre Syndrome After Trivalent Influenza Vaccination in Adults
por: Chang, Kuo-Hsuan, et al.
Publicado: (2019)

Assessment of trivalent live influenza vaccines in MDCK cell line
por: Landgraf, G., et al.
Publicado: (2021)

Community Acquired Pneumonia Incidence Among Children Under 5 Years of Age in Concordia Argentina. Universal Vaccination Impact
por: Rearte, Analía, et al.
Publicado: (2017)

Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact
por: Ruvinsky, Raúl O., et al.
Publicado: (2018)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant
por: McAdams, David, et al.
Publicado: (2021)

996. A Cluster-Randomized Trial of Adjuvanted Trivalent Influenza Vaccine vs. Standard Dose in US Nursing Homes
por: Gravenstein, Stefan, et al.
Publicado: (2018)

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h5ftc7sl054leqlse1chj4ga07